513 related articles for article (PubMed ID: 23291299)
1. Itraconazole and arsenic trioxide inhibit Hedgehog pathway activation and tumor growth associated with acquired resistance to smoothened antagonists.
Kim J; Aftab BT; Tang JY; Kim D; Lee AH; Rezaee M; Kim J; Chen B; King EM; Borodovsky A; Riggins GJ; Epstein EH; Beachy PA; Rudin CM
Cancer Cell; 2013 Jan; 23(1):23-34. PubMed ID: 23291299
[TBL] [Abstract][Full Text] [Related]
2. Targeting of the Hedgehog signal transduction pathway suppresses survival of malignant pleural mesothelioma cells in vitro.
You M; Varona-Santos J; Singh S; Robbins DJ; Savaraj N; Nguyen DM
J Thorac Cardiovasc Surg; 2014 Jan; 147(1):508-16. PubMed ID: 24094913
[TBL] [Abstract][Full Text] [Related]
3. Hedgehog pathway inhibition and the race against tumor evolution.
Atwood SX; Chang AL; Oro AE
J Cell Biol; 2012 Oct; 199(2):193-7. PubMed ID: 23071148
[TBL] [Abstract][Full Text] [Related]
4. Hedgehog fights back: mechanisms of acquired resistance against Smoothened antagonists.
Metcalfe C; de Sauvage FJ
Cancer Res; 2011 Aug; 71(15):5057-61. PubMed ID: 21771911
[TBL] [Abstract][Full Text] [Related]
5. Arsenic trioxide inhibits human cancer cell growth and tumor development in mice by blocking Hedgehog/GLI pathway.
Beauchamp EM; Ringer L; Bulut G; Sajwan KP; Hall MD; Lee YC; Peaceman D; Ozdemirli M; Rodriguez O; Macdonald TJ; Albanese C; Toretsky JA; Uren A
J Clin Invest; 2011 Jan; 121(1):148-60. PubMed ID: 21183792
[TBL] [Abstract][Full Text] [Related]
6. Smoothened mutation confers resistance to a Hedgehog pathway inhibitor in medulloblastoma.
Yauch RL; Dijkgraaf GJ; Alicke B; Januario T; Ahn CP; Holcomb T; Pujara K; Stinson J; Callahan CA; Tang T; Bazan JF; Kan Z; Seshagiri S; Hann CL; Gould SE; Low JA; Rudin CM; de Sauvage FJ
Science; 2009 Oct; 326(5952):572-4. PubMed ID: 19726788
[TBL] [Abstract][Full Text] [Related]
7. Hedgehog- and mTOR-targeted therapies for advanced basal cell carcinomas.
Piérard-Franchimont C; Hermanns-Lê T; Paquet P; Herfs M; Delvenne P; Piérard GE
Future Oncol; 2015 Nov; 11(22):2997-3002. PubMed ID: 26437034
[TBL] [Abstract][Full Text] [Related]
8. Arsenic: a potentially useful poison for Hedgehog-driven cancers.
Raju GP
J Clin Invest; 2011 Jan; 121(1):14-6. PubMed ID: 21183780
[TBL] [Abstract][Full Text] [Related]
9. Clinical experience with Hedgehog pathway inhibitors.
Low JA; de Sauvage FJ
J Clin Oncol; 2010 Dec; 28(36):5321-6. PubMed ID: 21041712
[TBL] [Abstract][Full Text] [Related]
10. Hedgehog Pathway Inhibition.
Sekulic A; Von Hoff D
Cell; 2016 Feb; 164(5):831. PubMed ID: 26919418
[TBL] [Abstract][Full Text] [Related]
11. Itraconazole, a commonly used antifungal that inhibits Hedgehog pathway activity and cancer growth.
Kim J; Tang JY; Gong R; Kim J; Lee JJ; Clemons KV; Chong CR; Chang KS; Fereshteh M; Gardner D; Reya T; Liu JO; Epstein EH; Stevens DA; Beachy PA
Cancer Cell; 2010 Apr; 17(4):388-99. PubMed ID: 20385363
[TBL] [Abstract][Full Text] [Related]
12. Medicine. Disrupting Hedgehog may reverse advanced cancer, if only temporarily.
Kean S
Science; 2009 Sep; 325(5945):1188. PubMed ID: 19729622
[No Abstract] [Full Text] [Related]
13. Arsenic antagonizes the Hedgehog pathway by preventing ciliary accumulation and reducing stability of the Gli2 transcriptional effector.
Kim J; Lee JJ; Kim J; Gardner D; Beachy PA
Proc Natl Acad Sci U S A; 2010 Jul; 107(30):13432-7. PubMed ID: 20624968
[TBL] [Abstract][Full Text] [Related]
14. Smoothened variants explain the majority of drug resistance in basal cell carcinoma.
Atwood SX; Sarin KY; Whitson RJ; Li JR; Kim G; Rezaee M; Ally MS; Kim J; Yao C; Chang AL; Oro AE; Tang JY
Cancer Cell; 2015 Mar; 27(3):342-53. PubMed ID: 25759020
[TBL] [Abstract][Full Text] [Related]
15. RAS/MAPK Activation Drives Resistance to Smo Inhibition, Metastasis, and Tumor Evolution in Shh Pathway-Dependent Tumors.
Zhao X; Ponomaryov T; Ornell KJ; Zhou P; Dabral SK; Pak E; Li W; Atwood SX; Whitson RJ; Chang AL; Li J; Oro AE; Chan JA; Kelleher JF; Segal RA
Cancer Res; 2015 Sep; 75(17):3623-35. PubMed ID: 26130651
[TBL] [Abstract][Full Text] [Related]
16. Small molecule inhibition of GDC-0449 refractory smoothened mutants and downstream mechanisms of drug resistance.
Dijkgraaf GJ; Alicke B; Weinmann L; Januario T; West K; Modrusan Z; Burdick D; Goldsmith R; Robarge K; Sutherlin D; Scales SJ; Gould SE; Yauch RL; de Sauvage FJ
Cancer Res; 2011 Jan; 71(2):435-44. PubMed ID: 21123452
[TBL] [Abstract][Full Text] [Related]
17. Smoothened (SMO) receptor mutations dictate resistance to vismodegib in basal cell carcinoma.
Pricl S; Cortelazzi B; Dal Col V; Marson D; Laurini E; Fermeglia M; Licitra L; Pilotti S; Bossi P; Perrone F
Mol Oncol; 2015 Feb; 9(2):389-97. PubMed ID: 25306392
[TBL] [Abstract][Full Text] [Related]
18. Effects of Combined Treatment With Arsenic Trioxide and Itraconazole in Patients With Refractory Metastatic Basal Cell Carcinoma.
Ally MS; Ransohoff K; Sarin K; Atwood SX; Rezaee M; Bailey-Healy I; Kim J; Beachy PA; Chang AL; Oro A; Tang JY; Colevas AD
JAMA Dermatol; 2016 Apr; 152(4):452-6. PubMed ID: 26765315
[TBL] [Abstract][Full Text] [Related]
19. Locally advanced and metastatic basal cell carcinoma: molecular pathways, treatment options and new targeted therapies.
Ruiz Salas V; Alegre M; Garcés JR; Puig L
Expert Rev Anticancer Ther; 2014 Jun; 14(6):741-9. PubMed ID: 24611655
[TBL] [Abstract][Full Text] [Related]
20. A new era for an ancient drug: arsenic trioxide and Hedgehog signaling.
Beauchamp EM; Uren A
Vitam Horm; 2012; 88():333-54. PubMed ID: 22391311
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
